Physician profile
Lawrence Macdonald
NPI 1104868967
$12,644.78
in general payments reported to CMS, 2019-2025
10 companies · $60.41 in 2025
The $60.41 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $145 · 2021: $259 · 2022: $11K · 2023: $435 · 2024: $101 · 2025: $60.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.73 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,176.06 | 2022-2024 | Da Vinci Surgical System |
| Jazz Pharmaceuticals INC. | $670.58 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $509.54 | 2019-2023 | Tezspire |
| Ethicon INC. | $98.98 | 2020 | |
| Resmed Corp | $55.65 | 2019-2023 | |
| Grifols USA, LLC | $38.50 | 2021-2022 | |
| Glaxosmithkline, LLC. | $31.98 | 2024-2025 | Trelegy Ellipta, Nucala |
| Insmed, INC. | $25.18 | 2025 | Arikayce |
| Pulmonx Corporation | $21.45 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Merck Sharp & Dohme LLC | $16.86 | 2024 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.